Retrospective Analysis of the Development of Human Thyroglobulin during Pregnancy in Patients with Treated Non-Recurrent Differentiated Thyroid Cancer

Current Oncology

Jennifer Staudt¹  Amir Sabet²  Justus Baumgarten²  Daniel Groener²  Christian Happel²  Frank Grünwald²  Benjamin Bockisch²  Thomas Rink² 

[1]Department of Nuclear Medicine, Medizinisches Versorgungszentrum (MVZ), D-63739 Aschaffenburg, Germany

[2]Department of Nuclear Medicine, University Hospital, Goethe University, Theodor Stern Kai 7, D-60590 Frankfurt, Germany

关键词: differentiated thyroid carcinoma;    thyroidectomy;    radioiodine therapy;    thyroglobulin;    pregnancy;   

DOI  :  10.3390/curroncol29060320

来源: DOAJ

【 摘 要 】

Aim: Therapy success in patients with differentiated thyroid cancer (DTC) after thyroidectomy and radioiodine therapy (RIT) is proven by permanent decrease in human thyroglobulin (hTg) to <1 ng/mL. In this retrospective analysis hTg development before, during and after pregnancy were analyzed. Material and methods: A descriptive analysis of hTg courses in 47 women with 57 pregnancies under levothyroxine substitution was performed after treatment of DTC without evidence of residual or recurrent disease. We compared hTg levels before, during and after pregnancies. A median of four measurements were performed during pregnancy. Results: In five out of the 47 patients at least one hTg increase to ≥1.0 ng/mL occurred during pregnancy (P1: 1.1; P2: 1.75; P3: 1.0; P4: 1.1; P5: 1.07 ng/mL). In another three cases an increase to ≥0.5 ng/mL occurred. After delivery, all patients returned to undetectable hTg levels. Human Tg maxima during pregnancy were significantly elevated according to Friedman´s Chi2 and p Holm–Bonferroni. Conclusion: In women with ablative thyroid therapy after DTC, a temporary elevation in hTg levels during pregnancy may occur. The reason therefore remains unclear and requires further investigation.

【 授权许可】

Unknown